$Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience$

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Abstract Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospec...

Full description

Bibliographic Details
Main Authors:	Young‐Woo Jeon, Seugyun Yoon, Gi June Min, Sung‐Soo Park, Silvia Park, Jae‐Ho Yoon, Sung‐Eun Lee, Byung‐Sik Cho, Ki‐Seong Eom, Yoo‐Jin Kim, Hee‐Je Kim, Seok Lee, Chang‐Ki Min, Jong Wook Lee, Seok‐Goo Cho
Format:	Article
Language:	English
Published:	Wiley 2019-11-01
Series:	Cancer Medicine
Subjects:	allogeneic stem transplantation bendamustine ibrutinib mantle cell lymphoma nonresponder
Online Access:	https://doi.org/10.1002/cam4.2565

Similar Items

Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
by: Danuta Krasowska, et al.
Published: (2020-09-01)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
by: Michael Wang, et al.
Published: (2017-11-01)

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
by: Aliénor Galinier, et al.
Published: (2017-01-01)

Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice
by: Vladimir I. Vorobyev, et al.
Published: (2021-07-01)

Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice
by: VI Vorob’ev, et al.
Published: (2019-03-01)

Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review
by: Jessica D. Rich, et al.
Published: (2019-10-01)

Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma
by: Marcus Høy Hansen, et al.
Published: (2021-01-01)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
by: Antonio Cuneo, et al.
Published: (2020-11-01)

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
by: Samip Master, et al.
Published: (2017-06-01)

Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment
by: Viktoria Fuhr, et al.
Published: (2021-02-01)

Ibrutinib: A narrative drug review
by: Pritesh Naresh Munot, et al.
Published: (2020-01-01)

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
by: Zhuojun Liu, et al.
Published: (2021-06-01)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
by: Denlinger NM, et al.
Published: (2018-03-01)

Severe CMV infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in an old mantle cell lymphoma patient
by: Gabriele Magliano, et al.
Published: (2021-08-01)

Multifocal periungual granulation tissue related to ibrutinib therapy
by: Aatman Shah, MD, et al.
Published: (2020-02-01)

Clinical Approach to Nonresponsive Pneumonia in Adults Diagnosed by a Primary Care Clinician: A Retrospective Study
by: Kiley B. Vander Wyst, et al.
Published: (2016-04-01)

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
by: Anna Mair, et al.
Published: (2021-09-01)

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
by: Alexandra Albertsson-Lindblad, et al.
Published: (2019-08-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
by: Sarah Cadot, et al.
Published: (2020-12-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Ferrarini, I., et al.
Published: (2022)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
by: Sawalha Y, et al.
Published: (2020-07-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Imbruvica (Ibrutinib) induced subcutaneous hematoma: A case report
by: Chinmay Jani, et al.
Published: (2021-03-01)

Ibrutinib-associated pityriasis rosea–like rash
by: Carole Bitar, MD, et al.
Published: (2018-01-01)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
by: Sawalha Y, et al.
Published: (2020-09-01)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
by: Jae‐Ho Yoon, et al.
Published: (2019-12-01)

Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia
by: Anantha Sriharsha Madgula, MBBS, et al.
Published: (2020-09-01)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
by: Khan M, et al.
Published: (2017-03-01)

Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia
by: Josh A. Hammel, MD, et al.
Published: (2017-05-01)

Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells
by: Laia Sadeghi, et al.
Published: (2020-05-01)

Safety and efficacy of ibrutinib in a patient with severe renal impairment
by: Kalman Filanovsky, et al.
Published: (2017-09-01)

Anti-Tumorigenic and Immunomodulatory Effects of Ibrutinib Against Hepatocellular Carcinoma
by: Elkholy, Khadija Hassan
Published: (2017)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report
by: Maximilian Higer, et al.
Published: (2020-08-01)

Infections in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib: Incidence and Predisposing Factors
by: EA Dmitrieva, et al.
Published: (2019-09-01)

Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.
by: John Xie, et al.
Published: (2021-01-01)

Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstrom’s macroglobulinemia and review of the literature
by: Anders Bisgaard Jensen, et al.
Published: (2017-04-01)